New hope for tough lupus cases: experimental therapy UB-VV410 enters human testing
NCT ID NCT07109986
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests an experimental drug called UB-VV410 in 21 adults with active lupus (including lupus nephritis) that hasn't improved with standard treatments. The main goals are to check safety, find the best dose, and see early signs of effectiveness. Participants will receive the drug by IV and be closely monitored for side effects and disease activity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Nanjing Medical University
RECRUITINGNanjing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple blood test may reveal kidney damage in lupus — no biopsy needed?
- Can a Three-Drug combo quiet lupus kidney flares?
- Can a new biologic tame lupus flares?
- Could a single injection tame lupus and Sjögren's?
- Can a single infusion tame tough lupus?
- Can a single drug calm three different autoimmune diseases? a new trial puts ATG-201 to the test.